why choose us

First received: November 02, 2022

Clinical Trial: Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Chronic Obstructive Pulmonary Disease

Study Type: INTERVENTIONAL


Official Title: A Multicenter, Randomized, Single-Blind, Placebo-Parallel-Controlled Research of REGEND001 Cell Therapy for Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect

Brief Summary: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow.In a large number of patients, diffusion function is impaired along with the progression of disease.REGEND001 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment.In this study, a multicenter, randomized, single-blind, placebo-parallel-controlled trial is performed to assess the efficacy and safety of REGEND001…

Read more